Abzu is a specialized explainable AI platform for pharmaceutical R&D focused on designing RNA therapeutics. It helps research teams develop safer, more effective drug candidates using both small and complex datasets.
RNA Therapeutic Design with AI
Abzu applies AI to design and prioritize compounds for RNA-based therapies, including:
siRNA
anti-miR
antisense oligonucleotides (ASO)
Its algorithms account for key biological factors such as:
thermodynamics
genetic variation
other relevant biological parameters
Explainability and Small-Data Modeling
Rather than operating as a “black box,” Abzu emphasizes transparency and interpretability. Researchers can see not only the recommended structures, but also the reasoning behind the model’s suggestions. The platform is designed to work well with limited datasets, which is often critical in early-stage R&D.
Who It’s For
Abzu is built for teams working on RNA therapeutics and target discovery, including:
pharmaceutical companies
biotech startups
academic labs
By narrowing down the number of candidates to test experimentally, Abzu helps teams focus resources on the most promising options and move from hypothesis to preclinical and clinical work more efficiently.
